Infliximab Serum Level Assessment After Switching from Intravenous to Subcutaneous Administration: The ISLASIS Study. (PubMed, Clin Exp Gastroenterol) - Oct 12, 2026 - "This investigator-initiated prospective observational study was not registered in a clinical trial registry because treatment allocation was not determined by the study protocol. All participants received standard-of-care treatment, and the decision to switch from intravenous to subcutaneous infliximab was made as part of routine clinical practice."
Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis
|
|
Bianca Loyo Pona Schiavetti; Rodrigo Galhardi Gasparini
|